Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) status in ovarian adult granulosa cell tumours

Histopathology

Volumn 64, Issue 5, 2014, Pages 633-638

  Higgins, Patricia A ^a,b   Brady, Aidan ^b   Dobbs, Stephen P ^b   Salto Tellez, Manuel ^a,b   Maxwell, Perry ^a,b   Mccluggage, W Glenn ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Adult granulosa cell tumour; Epidermal growth factor receptor; Immunohistochemistry; Mutation analysis; Ovary; Tyrosine kinase; Tyrosine kinase inhibitors

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOMATOMEDIN C RECEPTOR; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN;

ADULT; ADULT GRANULOSA CELL TUMOR; AGED; ARTICLE; CLINICAL ARTICLE; EGFR GENE; EXON; FEMALE; GENE; GRANULOSA CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GRANULOSA CELL TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1;

EID: 84896135160     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12322     Document Type: Article

References (19)

1. Fox H. Pathological prognostic factors in early stage adult-type granulosa cell tumours of the ovary. Int. J. Gynaecol. Cancer 2003; 13; 1-4.
2. Miller K, McCluggage WG. Prognostic factors in ovarian adult granulosa cell tumours. J. Clin. Pathol. 2008; 61; 881-884.
3. Koukourakis GV, Kouloulias VE, Koukourakis MJ et al. Granulosa cell tumor of the ovary: tumor review. Integr. Cancer Ther. 2008; 7; 204-215.
4. Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol. Oncol. 2004; 96; 865-869.
5. Leibl S, Bodo K, Gogg-Kammerer M et al. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3 and Her-4: an immunohistochemical study. Gynecol. Oncol. 2006; 101; 18-23.
6. Nofech-Mozes S, Ismiil N, Dube V et al. Immunohistochemical characterization of primary and recurrence adult granulosa cell tumors. Int. J. Gynecol. Pathol. 2012; 31; 80-90.
7. Pirker R, Pereira JR, Pawel JV et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advances non-small-cell lung cancer:analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012; 13; 33-42.
8. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature 2007; 7; 169-180.
9. Dunn G, Emsley R, Liu H, Landau S. Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine. Clin. Trials 2013; 10; 709-719.
10. Rude Voldborg B, Damstrup L, Spang-Thomsen M, Skovgaard Poulsen H. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 1997; 8; 1197-1206.
11. Arteaga C. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7 (Suppl. 4); 31-39.
12. Li C, Sun Y, Fang Z et al. Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma. J. Thorac. Oncol. 2011; 6; 1016-1021.
13. Lam KC, Mok TS. Targeted therapy: an evolving world of lung cancer. Respirology 2011; 16; 13-21.
14. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005; 315; 971-979.
15. Cadranel J, Zalcman G, Sequist L. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur. Respir. J. 2011; 37; 183-193.
16. Boyle DP, Mullan P, Salto-Tellez M. Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: a comprehensive review of biomarkers related to therapeutic interventions. Biochim. Biophys. Acta 2013; 1835; 230-342.
17. Sanford M. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. Drugs 2013; 73; 1605-1615.
18. Nakagawa M, Uramoto H, Shimokawa H, Onitsuka T, Hanagiri T, Tanaka F. Insulin-like growth factor receptor-1 expression predicts postoperative recurrence in adenocarcinoma of the lung. Exp. Ther. Med. 2011; 2; 585-590.
19. Hailey J, Maxwell E, Koukouras W et al. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumour cells. Mol. Cancer Ther. 2002; 1; 1349-1353.